These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31801415)

  • 21. Emerging drugs for uveitis.
    Larson T; Nussenblatt RB; Sen HN
    Expert Opin Emerg Drugs; 2011 Jun; 16(2):309-22. PubMed ID: 21210752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of drugs used in the treatment of ocular inflammatory diseases.
    Lima BR; Nussenblatt RB; Sen HN
    Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):875-82. PubMed ID: 23521173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between Immunosuppressive Drugs and Coronavirus Disease 2019 Outcomes in Patients with Noninfectious Uveitis in a Large US Claims Database.
    Sun Y; Miller DC; Akpandak I; Chen EM; Arnold BF; Acharya NR
    Ophthalmology; 2022 Oct; 129(10):1096-1106. PubMed ID: 35588945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview and recent developments in the medical management of paediatric uveitis.
    Pilly B; Heath G; Tschuor P; Lightman S; Gale RP
    Expert Opin Pharmacother; 2013 Sep; 14(13):1787-95. PubMed ID: 23826652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis.
    Papaliodis GN; Yu Y; Brill DA; Sobrin L; VanderBeek B
    Am J Ophthalmol; 2024 Sep; 265():241-247. PubMed ID: 38679356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local versus Systemic Therapy for Noninfectious Uveitis (NIU).
    Chang EL; Sobrin L
    Semin Ophthalmol; 2023 Jan; 38(1):15-23. PubMed ID: 36471661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the pharmacotherapy of uveitis: the art of personalized care.
    Patel SH; Belamkar A; Hajrasouliha AR; Jusufbegovic D; Ciulla TA
    Expert Opin Pharmacother; 2022 Aug; 23(12):1445-1455. PubMed ID: 35880543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials.
    Thng ZX; Bromeo AJ; Mohammadi SS; Khatri A; Tran ANT; Akhavanrezayat A; T T Than N; Nguyen KS; Yoo WS; Mobasserian A; Or CCM; Nguyen QD
    Expert Opin Emerg Drugs; 2023 Dec; 28(4):297-309. PubMed ID: 38129984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond.
    Karkhur S; Hasanreisoglu M; Vigil E; Halim MS; Hassan M; Plaza C; Nguyen NV; Afridi R; Tran AT; Do DV; Sepah YJ; Nguyen QD
    J Ophthalmic Inflamm Infect; 2019 Sep; 9(1):17. PubMed ID: 31523783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroid-sparing agents: new treatment options.
    Tomkins-Netzer O; Taylor SR; Lightman S
    Dev Ophthalmol; 2012; 51():47-56. PubMed ID: 22517203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment.
    Dehoorne JL; Groth H; Carlé E; De Schrijver I; Sys C; Delbeke P; Kreps EO; Renson T; Bonroy C
    Pediatr Rheumatol Online J; 2023 Dec; 21(1):148. PubMed ID: 38124137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adalimumab for the treatment of uveitis.
    LaMattina KC; Goldstein DA
    Expert Rev Clin Immunol; 2017 Mar; 13(3):181-188. PubMed ID: 28140700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of noninfectious uveitis.
    Ferreira LB; Farrall AL; Furtado JM; Smith JR
    Arq Bras Oftalmol; 2021; 84(6):610-621. PubMed ID: 34431877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for noninfectious uveitis: what may be coming to the clinics.
    Maya JR; Sadiq MA; Zapata LJ; Hanout M; Sarwar S; Rajagopalan N; Guinn KE; Sepah YJ; Nguyen QD
    J Ophthalmol; 2014; 2014():310329. PubMed ID: 24868451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New pharmacotherapy options for noninfectious posterior uveitis.
    Pleyer U; Stübiger N
    Expert Opin Biol Ther; 2014 Dec; 14(12):1783-99. PubMed ID: 25243865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
    Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
    Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TNF inhibition for ophthalmic indications: current status and outlook.
    Rifkin LM; Birnbaum AD; Goldstein DA
    BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.